In a recent study of gouty subjects, urinary excretion of uric acid was noted to be greater in the symptomatic than in the asymptomatic subjects (1). Since, however, the groups of patients were small and the data unpaired, these observations were not analyzed further. A The present study was designed to extend our previous findings by obtaining paired data from gouty men during symptomatic and asymptomatic phases of their disease, simultaneously eliminating, whenever possible, other factors that might influence uric acid metabolism and turnover.
In a recent study of gouty subjects, urinary excretion of uric acid was noted to be greater in the symptomatic than in the asymptomatic subjects (1) . Since, however, the groups of patients were small and the data unpaired, these observations were not analyzed further. A review of published reports revealed lack of agreement about changes in serum and urinary uric acid during clinically active gout. Brochner-Mortensen (2) , summarizing publications to 1939, called attention to German reports that uric acid excretion increased greatly during acute attacks of gout and subsided thereafter. Brochner-Mortensen consiclered, however, that the reported fluctuations in uric acid excretion were inconstant when set against variations in medication and diet. Despite individual case reports indicating increased uricosuria during gouty attacks (3, 4), Stetten's view that "when an acute attack does occur no consistent changes in the quantity of uric acid in blood or urine are observed" (5) , represents the consensus of current opinion.
The present study was designed to extend our previous findings by obtaining paired data from gouty men during symptomatic and asymptomatic phases of their disease, simultaneously eliminating, whenever possible, other factors that might influence uric acid metabolism and turnover.
METHODS
Over a 2-year span, data were collected from eleven subjects judged suitable for this study. All were men with previously established diagnoses of primary gout, with no detectable nephropathy, and with totally asymptomatic intercritical intervals. Pertinent data for all subjects are listed in Table I . Only three were later eliminated, two for failure to collect total urine output, and one because of the inadvertent medication with a uricosuric drug during a symptomatic episode. Ten of the subj ects were followed over a single hospital ad-* Work supported by U. S. Public Health Service research grant AI 02757-05 from the National Institute of Allergy and Infectious Diseases, Bethesda, Md. mission; eight were admitted with acute arthritis and were studied before and after therapy with colchicine and relief of symptoms. The remaining two, RC and FC, were admitted for unrelated reasons and developed acute arthritis during the study. The eleventh subject, LM, was seen over two separate admissions, once for acute arthritis, when only acute-phase data were studied, and again, 2 years later, during ambulatory convalescence from myocardial infarction.
None of the subjects were on uricosuric drugs before the study. They were all fed a standard low-purine diet from at least 2 days before the start of the study. The daily diet contained 96 g protein, 85 g fat, and 257 g carbohydrate; the purine content was limited to 60 mg contained in one meat course given each day. Dietary intake was supervised daily. Three normal persons fed this diet for 7 to 11 days each stabilized their urinary excretion of uric acid within 24 to 48 hours, and thereafter their daily uric acid excretion did not vary by more than 68 mg from their individual mean 24-hour uric acid excretion. The subjects' total urine output was collected in 24-hour samples starting and ending at 8 :30 a.m. Blood was drawn each day at the same hour. Collection and preservation of urine has been described (6) . Uric acid was measured by the spectrophotometric method of Praetorius and Poulsen (7) with uricase, and creatinines were determined by Phillips' modification of the alkaline picrate method (8) . Urinary 17-hydroxycorticosteroids were analyzed by the method of Silber and Porter (9) .
Therapy during the acute phase of the study was limited to nonuricosuric analgesics. The acute phase of the study was terminated by iv colchicine therapy in order to avoid any possible gastroenteritis that might interfere with urine collection. The usual regimen was 3 mg intravenously, followed in 12 hours by maintenance oral medication. Six of the eight subjects admitted with acute arthritis responded within 24 to 48 hours. The remaining two required a second iv dose and were free of symptoms within 72 hours. Data obtained during this transitional phase are not included in this study, and showed only decreases in uric acid excretion to levels observed in the asymptomatic period. The asymptomatic phase of the study was marked from the time at wvhich the patient became afebrile, ambulatory, and free of objective signs of arthritis or inflammation.
RESULTS
Clinical laboratory data from the eleven gouty subjects are listed in or relative leukocytosis during the symptomatic asymptomatic. For the remaining three subperiod. Also, all five subjects so studied had in-jects (DF, PG, and JC), data were collected for creased 24-hour urinary 17-hydroxycorticosteroid only 2 days for each period, since they received excretion during the arthritic state. colchicine after the second day of the acute-phase Eight of the eleven subjects were observed for study. The data are summarized in Table II The failure to observe any significant changes in the serum uric acid of the gouty subjects during the two clinical phases prompted an additional study. Similar studies were conducted on a group of nongouty persons with inflammation and obviously increased nucleic acid production. Table  IV lists the data obtained from seven subjects with acute nongouty arthritis or suppurative lung disease. In all seven, uric acid excretion and clearance were considerably elevated, despite the absence of hyperuricemia. Serum uric acid levels ranged from 2.2 to 4.7 mg per 100 ml, well within the normal range, whereas urinary excretion and clearance ranged from 733 to 1,330 mg per 24 hours and 15.6 to 29.0 ml per minute, values two to three times the normal.
DISCUSSION
Our observations raise two questions. First, what is the source or mechanism of the increased uric acid excretion and clearance in symptomatic gout? Second, are these changes the cause or the result of the arthritis? If a significant change in serum uric acid had accompanied the increased uric acid excretion, then these changes could have been attributed to either increased production of uric acid, or increased renal tubular clearance, depending on the direction of change in serum levels. Certain observations, reported both here and previously, favor increased production of uric acid as the mechanism for the increased excretion. The leukocytosis observed during the symptomatic state (Table I) indicates increased nucleic acid production and, after degeneration of the leukocytes in the inflammatory area, increased uric acid production. A previously reported observation on the ability of iv administered desoxyribonuclease to increase uric acid excretion in symptomatic gouty subjects tends to confirm this concept (1). This enzyme, a DNA depolymerase, is capable of diffusing into inflammatory areas and depolymerizing DNA derived from susceptible leukocytes (11) (12) (13) .
The failure to demonstrate an increase in serum uric acid levels argues against the concept of increased production. Recent studies have shown that increased uric acid load, in addition to producing increased renal clearance of uric acid, also increases serum levels (14-16). The observation, however, of normal serum uric acid levels in nongouty subjects with increased uric acid production secondary to suppurative and inflammatory diseases (Table IV) suggests that inflammation may modify the host response to an increased uric acid load. The increased urinary excretion of 17-hydroxycorticosteroids during the symptomatic state by five of the gouty subjects (Table I) implies an increased secretion of adrenal steroids during the pain and stress of the arthritis that would produce renal uricosuria (17) and possibly decrease serum levels despite an increased load.
The second question, whether the increased excretion of uric acid is a cause or effect of the arthritis, must also be answered speculatively. The increased uric acid excretion by two subjects before development of clinical arthritis (Table  III) indicates the increase may be causally related. The classical observations that leukocytosis-stimulating episodes such as infection, surgery, or trauma are precipitating causes of arthritis (18) (19) (20) support this possibility. The arthritis itself, however, will stimulate further leukocytic response, and further nucleic acid and uric acid production, and, as Seegmiller, Laster, and Howell postulate, the inflammatory reaction becomes selfsustaining and self-enhancing (21) .
SUM MARY
Data demonstrate that gouty subjects have a greater excretion and clearance of uric acid while they are symptomatic, but that their serum levels do not change predictably with the symptoms. The cause of these changes is unknown, but the leukocytosis and increased 17-hydroxycorticosteroid excretion observed during the arthritic state suggest the combined involvement of increased production of uric acid and steroid-induced renal uricosuria.
